ArticleAAPS PharmSciTech2025
Mucoadhesive Carbohydrate-Based Polymeric Nanocapsule Loaded with Palbociclib for Enhanced GIT Retention and In Vitro Anticancer Efficacy in MDA-MB-231 Cells.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment.Drug delivery and translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) continues to be a significant global health issue, with triple-negative breast cancer being one of the most aggressive forms. Palbociclib (PAL) has shown promising results in BC therapy but suffers from low solubility, poor oral bioavailability, and variable systemic absorption. A polymeric nanocapsule based on PAL-loaded dextran (PAL-DEX-PNC) was developed to enhance its solubility, stability, gastrointestinal tract (GIT) retention and anticancer efficacy. The optimised PAL-DEX-PNC exhibited a particle size, PDI, zeta potential and percentage entrapment efficiency of 217.8 ± 2.15 nm, 0.24 ± 0.03, 1.72 ± 1.07 mV, and 99.71 ± 3.1%, respectively. PAL-DEX-PNC had sufficient storage stability of 60 days at 2-8°C, in simulated GIT conditions and DMEM cell culture media. The PAL release from PAL-DEX-PNC at pH 5.5 and 7.4 was 70.05 ± 3.02% and 62.46 ± 3.43%, respectively, sustained for a period of 48 h. The ex vivo permeability studies confirmed an 8.85-fold increase in drug permeability for PAL-DEX-PNC compared to free PAL. The in vitro cytotoxicity assessment on MDA-MB-231 cells revealed that PAL-DEX-PNC has significantly greater cytotoxic potential than free PAL, with a 3.49-fold decreased IC
Indexed as
Identifiers
41239020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.